Appropriate Duration of Anti-Platelet straTegy in patients with advance Chronic Kideny Disease after new generation drug eluting stents (ADAPT-CKD)

Not Applicable

Recruiting

Conditions: Diseases of the genitourinary system

Registration Number: KCT0005775

Lead Sponsor: Yonsei University Health System, Severance Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 900

Inclusion Criteria

1. Over 19 years old
2. Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR <45 / <30 / <15 or dialysis)
3. Patients treated with a new generation drug eluting stent.
4. Patients who signed consent form

Exclusion Criteria

1. Over 85 years old
2. Patients with high risk of bleeding
1) History of hemorrhagic stroke
2) Stroke, dementia or central nervous system damage within 1 year
3) Head trauma or brain surgery within 6 months
4) Tumor in the skull
5) If aortic dissection is suspected
6) Internal bleeding within 6 weeks
7) In case of active bleeding or bleeding disorder
8) In case of major surgery, trauma or bleeding within 3 weeks
3. Patients who need oral anticoagulant
4. Pregnant women or women of childbearing age
5. Life expectancy is less than 1 year
6. Patients with a history of intracranial bleeding
7. Moderate to severe hepatic impairment (Child-Pugh class B or C)

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
et Clinical adverse event (NACE) : all cause death, myocardial infarction, stent thrombosis, stroke, major bleeding (BARC 3,5)

Secondary Outcome Measures

Name	Time	Method
target vessel revascularization;Each component of NACE (all cause death, myocardial infarction, stent thrombosis, stroke, major bleeding);BARC 2,3,5 bleeding;cardiovascular death;target lesion revascularization